Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases (RADAR)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT00466102
First received: April 25, 2007
Last updated: August 29, 2012
Last verified: August 2012

April 25, 2007
August 29, 2012
December 2006
December 2010   (final data collection date for primary outcome measure)
To determine the time to progression (TTP) in patients with no change in bone metastases after an 8 week run in treatment with RAD001 compared to placebo [ Time Frame: 40 weeks ] [ Designated as safety issue: No ]
To determine the time to progression (TTP) in patients with no change in bone metastases after an 8 week run in treatment with RAD001 compared to placebo
Complete list of historical versions of study NCT00466102 on ClinicalTrials.gov Archive Site
  • To determine the objective response rate after 8 weeks of RAD001 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • To determine the TTP in patients with a response after 8 weeks of RAD001 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • To determine the overall clinical benefit defined as CR, PR or stable disease > 24 weeks for patients continuing RAD001 after the 8 week run in phase [ Time Frame: 40 weeks ] [ Designated as safety issue: No ]
  • To evaluate the safety and toxicity of RAD001 [ Time Frame: 40 weeks ] [ Designated as safety issue: Yes ]
  • To assess the frequency of bone related events [ Time Frame: 40 weeks ] [ Designated as safety issue: Yes ]
  • To assess changes of pain intensity during treatment [ Time Frame: 40 weeks ] [ Designated as safety issue: Yes ]
  • To determine the objective response rate after 8 weeks of RAD001
  • To determine the TTP in patients with a response after 8 weeks of RAD001
  • To determine the overall clinical benefit defined as CR, PR or stable disease > 24 weeks for patients continuing RAD001 after the 8 week run in phase
  • To evaluate the safety and toxicity of RAD001
  • To assess the frequency of bone related events
  • To assess changes of pain intensity during treatment
Not Provided
Not Provided
 
Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases
RADAR: A Randomized Discontinuation Phase II Study to Determine the Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

The purpose of this study is to determine wether RAD001 can inhibit growth of tumour cells and/or stop the formation and activity of bone degrading osteoclasts.

RAD001 is an orally bioavailable and well tolerated rapamycin ester analogue, which acts by selectively inhibiting mTOR (mammalian target of rapamycin). mTor is an intracellular protein kinase implicated in the control of cellular proliferation in neoplastic cells. Treatment with RAD001 has been shown to inhibit these signalling events and leads to growth retardation of tumour cells. In addition RAD001 in vitro stops the formation and activity of osteoclasts. Therefore a therapy of advanced breast cancer with progressive bone metastases seems to be reasonable with RAD001.

Comparison:

All patients receive RAD001 in an 8 week run in phase. Patients who show a response after 8 weeks will continue receiving RAD001. All patients with stable disease after the run in phase will be randomised to receive either RAD001 or placebo and will be followed up until progression of disease. Patients with progressive disease after the 8 week run in phase will be withdrawn from the trial.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Breast Cancer
  • Drug: RAD001
    Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
  • Drug: Placebo
    2 tablets are taken once daily during study therapy
  • Active Comparator: 1
    Patients with stable disease after 8 week run in randomized to RAD001 (blinded)
    Intervention: Drug: RAD001
  • Placebo Comparator: 2
    Patients with stable disease after 8 week run in receive placebo (blinded)
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
130
December 2012
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements.
  • Histologically confirmed invasive adenocarcinoma of the breast.
  • Primary tumour or metastasis negative or positive (≥ 10% positive stained cells) for oestrogen and/or progesterone receptor detected by immunohistochemistry.
  • Single or multiple bone metastasis (x-ray, CT or MRI) as only metastatic site.
  • Postmenopausal hormone receptor positive patients should have received an aromatase inhibitor in any given previous breast cancer therapy. Concurrent endocrine treatment for metastatic bone disease is obligatory. Previous treatment with bisphosphonates is allowed.
  • Up to one previous chemotherapy for metastatic disease is allowed.
  • Patients must have either measurable or non-measurable target lesions according to the WHO criteria.
  • At least 1 target lesion must be completely outside the radiation portal or there must be pathologic proof of progressive disease.
  • At least 2 weeks since major surgery with full recovery.
  • Complete staging within 4 weeks prior to registration.
  • Karnofsky performance status evaluation > 60%.
  • Age >18 years.
  • Absolute neutrophil count >1,500 cells/µl, platelet count >100,000 cells/µl.
  • Bilirubin >1.5x the upper normal limit for the institution (UNL); elevation of transaminases, alkaline phosphatase < 2.5x UNL and serum albumin < 30g/l. Normal renal function (creatinine >1.5x upper normal limit)
  • If of childbearing potential, negative pregnancy test. In addition the patient has to agree to use an effective method to avoid pregnancy for the duration of the study.

Exclusion Criteria:

  • Known hypersensitivity reaction to the compounds or incorporated substances (e.g. everolimus or sirolimus [rapamycin] or lactose).
  • Concurrent immunotherapy or hormone replacement therapy and use of hormonal contraceptives.
  • Need for chemotherapy or irradiation of bone metastasis during study treatment
  • HER2 positive primary tumour and/or lesion
  • Evidence of metastasis in other organs
  • Uncompensated diabetes mellitus; fasting value of blood sugar of >120 (mg/dl)
  • Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00 mmol/l) or > 12.0 mg/dl (3.00 mmol/l)
  • Abnormal renal function as evidenced by a calculated creatinine clearance < 30 ml/minute
  • Life expectancy of less than 3 months
  • Serious intercurrent medical or psychiatric illness that may interfere with the planned treatment (including AIDS and serious active infection).
  • History of other malignancy within the last 5 years which could affect the diagnosis or assessment of metastatic breast cancer
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
  • Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (e.g. rifabutin, rifampicin, clarithromycin, ketoconazole, itraconazole, ritonavir, telithromycin, erythromycin, verapamil, dilitazem) within the last 5 days or the expected need for these treatments during study participation.
  • Pregnant or nursing women.
  • The patient is not accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre which could be the Principal or Co-Investigator's site.
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00466102
GBG 41
Yes
German Breast Group
German Breast Group
Novartis
Principal Investigator: Nicolai Maass, MD, Prof. Universitätsfrauenklinik Aachen
German Breast Group
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP